Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2Michael Simons, Nicolas A.F. Chronos, James E. Udelson et al.|Circulation|2002Cited by 652
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation studyRoger J. Laham, Michael Simons, Nicholas Chronos et al.|Journal of the American College of Cardiology|2000Cited by 223
Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery DiseaseMark Bush, Nicolas A.F. Chronos, Michael Simons et al.|The Journal of Clinical Pharmacology|2001Cited by 48